Liaoning Pharmaceutical Foreign Trade Corporation was established in 1994 and is the holding company of Shanghai Pharmaceuticals Holding Co., Ltd. Over the years, our company has continuously consolidated the foundation of management, adjusted strategic positioning, deepened service innovation, accelerated industrial breakthroughs, focused on market service demand, integrated diversified business models, and took “drug distribution” as the core, based on the “mature terminal network of the three northeast provinces and Inner Mongolia”, we strive to promote diversified businesses such as supply chain extension services, tripartite logistics services, health management services, international trade and new retail to speed up the construction of “smart medicine” service system and gradually transform and upgrade to information-based and digital high-end health service enterprises to create new core competitiveness.

After years of development, the scale of our company continues to expand, business performance and brand reputation in the industry has become increasingly prominent. Our company had won the “credit AAA rating” honor for several years in a row. In 2020, our company continued to maintain multi-format coordinated development, sales reached RMB6.4 billion.In 2021, our company continued to maintain multi-format coordinated development, sales reached RMB7.84 billion.

Our company always takes “persevering and devoting itself to improving people’s healthy quality of life” as our mission, advocates the core values of “innovation, integrity, cooperation, tolerance and responsibility”, and relies on the brand and platform advantages of Shanghai Pharmaceuticals Holding Co., Ltd., we will thoroughly implement the policies of the CPC Central Committee, governments at all levels and superior groups, actively respond to industry changes, and constantly improve the ability of sustainable drug supply and security. Our company strives to provide comprehensive service solutions for upstream and downstream partners, provide customers and patients with more quality, safe and reasonably priced products and services, and make greater contributions to promoting the balanced development of the industry and promoting “healthy China”.